Diabetic Medicine: A Journal of the British Diabetic Association 1996: Vol 13 Index

7 Pages·1996·1.2 MB·English

Dm
INDEXES
AUTHOR INDEX
Abalkhail, B. A., 861 Azzopardi, J., 80 Broadbent, D. M., 850 Constantino, M. 1., 748
Abrams, P., 415 Brown, D., 592 Cooper, G. G., 281
Ader, M., S67 Badran, A., 337 Brown, F., 513 Cooper, M. B., 816
Adler, A. 1., 555 Baker, R., 513, 577 Brown, L. 525 Coppack, 5. W., 616
Adojaan, B., 97 Bakker, K., 555 Brown, P. M., 493 Couper, j. j., 531
Agardh, C-D., 487 Bancroft, j., 84 Brown, V., 56 Cox, D. I., 916
Agardh, C.-D., 218 Barkai, L., 254 Brudenell, j. M., 90 Crace, C., 565
Agius Muscat, H., 80 Barker, D. ]. P., 868 Bruno, G., 889 Cradock, 5., 565
Ahroni, |. H., 549, 967 Barnes, D., 1069 Buckenham, T., 527 Crerand, 5., 561
Airey, C. M., 389 Bates, D., 741 Buckley, M., 554 Critchley, j. A. |. H., 429
Aizawa, S., 5103 Beard, j., 726 Burden, M., 577 Cronin, C. C., 768
Akanji, A. O., 874 Beard, R. W., 226 Buxton, C., 5122 Crook, M. A., 238
Akanuma, Y., 511, 365 Beck-Nielsen, H., 578, 806 Byrne, M. M., 854 Croxson, 5. C. M., 198
Akerblom, H. K., 464 Bedford, C., 634 Cui, L., 663
Akhter, j., 189 Bedon, E., 259 Cabealawa, 5., 125 Cuomo, 5., 321
Al-5almi, 1. 5., 582 Beech, R., 56 Cacciatori, V., 709 Currie, C., 683
Albers, C., 894 Behar, A., 882 Callam, M., 726 Currie, C. |., 273
Alberti, K. C. M. M., 56, 133, Beks, P. j., 960 Campbell, K., 590
501, 874, 894, 927, 990 Belfiglio, M., 1017 Campbell, L. V., 780 Dahlqvist, C., 495
Alert, C. V., 574 Belgian Diabetes Registry, 415 Camps, 1., 953 Daily, G., 533
Alessis, C., 1051 Belicar, P., 1051 Candiloros, H., 646 Danielsen, N., 677
Alexander, W., 590 Bell, G. 1., 590 Capaldo, B., 321 Danne, T., 594
Alexiou, Z. P., 243 Bell, P. M., 504 Caputo, G. M., 517 d'Annunzio, G., 630
Alford, F., 578, 806 Bellavere, F., 709 Carinci, F., 1017 Darwish, A., 834
AM, K., 226 Bellini, C., 642 Carmain, J. A., 47 da 5ilva, A. F., 726
AM, M. A., 337 Bender, R., 536 Carnazzo, G., 771 Datchev, 5. D., 916
Allwinkle, J., 513 Benett, 1., 295 Carrington, A. L., 912 Davey, R., 916
AltenhOfer, F., 156 Berger, M., 536, 625 Cassar, ]., 605 Davies, M., 389
Bergman, R. N., 567 Cassell, P., 420 Davies, M. J., 594
Alvarsson, M., 537
Bergstom, R. W., 563 Cassone-Faldetta, M., 642 Davies, R., 554
Amado, J. A., 284
Berne, C., 528, 478 Cavaliere, D., 1017 Davignon, D., 967
Aman, j., 478, 729
Bertelsmann, F. W., 960 Cavallo-Perin, ?., 771 Davignon, D. R., 549
Amid S. A. Ill
Betteridge, D. ]., 816 Cavanagh, P. R., 517 Daw, J., 973
Ampudia, |., 625
Betts, P., 554 Cerasi, E., 5161 Dawson, A., 543
Andersen, P., 983
Bhatnagar, D., 139 Chadwick, |., 590 Day, J., 565, 207, 389
Anderson, |. H., 47
Bhatnagar, M. K., 771 Chan, J. C. N., 150, 429 Day, j. L., 564
Anderson, P. j., 429
Biarnes, j., 953 Chan, 5. P., 226 Dean, j. D., 297, 1069
Andrews, J., 513
Billett, D., 175 Chana, T., 284 de Chamvallins, M. M., 882
Anyaoku, V., 247
Binns, D., 72 Chantelau, E., 156 Deckert, T., 313
Afjelqvist, J., 487
Blauth, C., 5101 Chase, H. P., 47 de Heus-van Putten, M. A., 555
Apfel, J., 565
Bodansky, H. ]., 734 Chaya, 5., 120 Dejgaard, A., 983
Appleton, D., 741
Bodmer, C. W., 564 Cheng, H., 513 De Leeuw, 1., 415
Aquilina, O., 80 Boer, F., 175 Cheung, C. K., 150 Dellera, A., 709
Aravanitis, D., 1071 Borra, M., 771 Chiasson, J.-L., 523 DeLuise, M., 40
Ardawi, M. 5., 861 Borthwick, A. C., 325 Child, A. G., 748 De Mattia, G., 642
Ariyanayagam-Baksh, 5. M., 574 Bott, U., 536 Childhood Diabetes in Finland de Neeling, J. N. D., 960
Arkkila, P. E. T., 828 Boulakia, F. C., 882 5tudy Croup, 464 Deng, X. X., 663
Armstrong, M., 133, 341 Bouloukos, A., 434 Chinaglia, A., 771 Derben, P., 56
Arner, P., 585 Boulton, A., 527 Chisholm, D. J., 780 Desgranges, P., 726
Arnqvist, H. J., 1027 Boulton, A. j. M., 7, 512, 530, Chishty, V. A., 182 de 5onnaville, j. j. ]., 482
Aro, 5., 376 139, 674, 912, 979, 1033, Clark, A., 577 de Wolff, H., 560
Arvanitis, M. P., 243 1064 Clark, F., 741 Dhanjil, 5., 247
Asano, T., 598 Bourn, D. M., 938 Clauson, P., 471 Diamond, J. R., 247
Asfour, M. G., 582 Bouter, L. M., 960 Clements, D., 590 Di Bonito, P., 321
Ashwell, 5., 780 Bowden, D. W., 590 Coates, P. A., 519 Diemel, L. T., 679
Atkin, 5. L., 493, 589 Boyko, E. j., 563, 549, 555, 967 Cockram, C. 5., 150 Dige-Petersen, H., 544
Attalah, M., 882 Braddy, K. C., 47 Cogley, D., 561 Di 5tefano, F., 771
Attali, j.-R., 882 Bradley, C., 590 Coles, C., 565 Doddridge, M. C., 90
Audit Committee of the Vascular Brash, P. D., 526, 973 Collins, V. R., 125 Dodds, R., 543
5urgical 5ociety of Great Bravi, C., 642 ComolM, G., 630 Donaghue, K. C., 65
Britain and Ireland, 726 Brazier, j., 590 Connolly, V., 898 Donner, M., 646
Avery, P. J., 341 Brismar, K., 1000 Connor, H., 912 Dornan, T., 577
© 1996 by John Wiley & Sons, Ltd. DIABETIC MEDICINE, 1996; 13: 1075-1078 1075
i
Dm
INDEXES
Dornhorst, A., 226 Gamsu, H. R., 90 Hellsted, T., 165 Kaaja, R., 165
Dowse, G. K., 125, 441 Garcia, M. T., 284 Hendrich, E., 40 Kaburagi, Y., SI 03
Drouin, P., 646 Garg, S. K., 47 Henley, )., SI 01 Kadowaki, T., SI 03
Drury, P., SI 01 Gatenby, S. J., 358 Henry, R. R., SI 48 Kahn, S. E., S63
Drury, P. L., 90 Gatti, M., 630 Herman, W. H., 337 Kalogeropoulou, K., 434
Dullaart, R. P. F., 651 Gazis, A., 764 Herrick, S. E., S30 Kaneko, T., 365
Dunn, O. M., 564 Gemma, M. L., 709 Heywood, D. M., 720 Kangas, T., 376
Dunsmuir, W. D., 700 Genuth, S., S29 Higson, N., S6 Kantola, I. M., 828
Durrant, S., S65 George, E., 634 Hildebrandt, P., 450 Kapitza, C., 683
Durrington, P. N., 139, 297 Gerich, J., S33 Hilgertova, J., 800 Karlander, S., 471
Geroulakos, G., 247 Hill, J., S60 Kasuga, M., S87
Earle, K. A., 1071 Gerstein, H. C., 23 Hilsted, )., 544, 983 Katagiri, H., S98
Eckert, B., 218 Giannini, C., 675 Hinata, S.-l., 902 Katayama, S., 330
Edmonds, M., S27 Gibby, O., S27, SI 22 Hitman, G. A., 232, 420 Katsilambros, N. L., 243
Edmonds, M. E., S61 Gill, G. V., 996 Hodge, A. M., 441 Kawamura, T., 120
Eeley, E. A., 656 Gillmer, M., S43 Hodinaf, A., 800 Kawazu, S., 330
Efendic, S., 471 Gilman, D., 908 Hogg, H., 592 Keen, H., S3, S6
Egusa, G., SI 33 Godfrey, K. M., 868 Holdsworth, J., 726 Keinanen-Kiukaanniemi, S., 382
El-Bahghouti, N., 247 Goel, A., 771 Holler, C., 1044 Kelly, W. F., 72
Elkeles, R. S., 247 Gokal, R., 1033 Hollis, S., 979, 1033 Kerner, W., 594
Elliott, K., 72 Goke, B., 854 Holman, R. R., 656 Kesson, C. M., 898
Ellis, P. R., 358 Gold, A. E., 346 Holmes, S. A. V., 700 Khan, M. A., 189
Elphick, T., 207 Goldschmidt, H. M. G., 794 Holst, ]. |., SI 56, 544 Khan, N., 531
Elster, B., S65 Gomez, N., 953 Home, P., S6, S77, SI 22, 207, Kikuchi, M., S98, SI 51
Engelgau, M. M., 337 Gonzalez-Macfas, J., 284 392 Kirk, B. A., 170
Engling, U. S., 594 Gotzsche, L., 834 Hoogenberg, K., 651 Kitange, H. M., 990
Erik Henriksen, )., S78 Gotzsche, O., 834 Hopkinson, N., 182 Klenerman, L., S52, 561
Ernst, L., 482 Gower, )., S77 Horowitz, M., SI 6 Knibbs, S., S60
Ersanli, Z., 156 Grant, P. )., 720 Hosking, D. )., 170 Knight, A., S65
Estes, |. M., S43 Gray, A. M., 683 Hother-Nielson, O., S78 Knopfler, A., S43
Every, N., S27 Gray, M., SI 3 Hotta, N., 120 Knowles, A., S27
Ezenwaka, C. E., 874 Greenwood, R. H., 925 Hounsome, B., S43 Knowles, E. A., 1064
Gries, F. A., 674 Howard, N. )., 65 Kobayashi, T., S98
Grill, V., S37 Hoy, T., S60 Kober, L., 450
Fairchild, J. M., 65
Grimley Evans, |., 741 Huddle, K. R., 996 Kockum, I., 209
Fajans, S. S., S90
Grindey, S., SI 3 Hunter, M., S60 Koev, D. J., 916
Falorni, A., 209
Grosser, M., 536 Hutchesson, A. C. J., 594 Koeva, L. A., 916
Fava, S., 80
Gulliford, M. C., 574 Hvidberg, A., 544, 983 Kohner, E., SI 3
Fay, T., 170
Gutierrez, P., 84 llonen, |., 464 Koivisto, V. A., 376
Felton, A.-M., S65
Immonen, I., 165 Koivukangas, P., 382
Fenech, F. F., 80 Hackett, P. M. W., 683
Ingberg, C. M., 478, 729 Koihe, P. S., 281
Fenn, P., 683 Hadden, D. R., 656
Ingham, J. N., 238 Kolterman, O., S34
Ferguson, M. W. )., S30 Hagopian, W. A., 209
Inglefield, C. |., 281 Kong, M-F. S-C., 112
Fernandez Castaher, M., 683 Hagura, R., SI 09, SI 20
Inoue, I., 330 Kong, X. T., 663
Fernandez-Castaher, M., 953 Haldane, F., 133, 341
Ishihara, H., S98 Koopmans, P. P., S48
Fernyhough, P., 679 Hales, C. N., 771, 816, 868
Ishii, J., 330 Koppel, I., SI 3
Ferrannini, E., S5 Hall, A. P., 594
Islam, N., 189 Kosaka, K., S5, SI 09, SI 20, 365
Ferri, C., 642 Hall, G., S90
Iwamoto, Y., 365 Kovatchev, B., 916
Finn, L., S65 Hall, M., S43, SI 22
Krauze, I., 457
Fisher, E. ]., 758 Halter, |. B., S90
Krentz, A. J., 30, 587
Formica, C., 40 Hansen, L. P., 834 )aap, A. )., 102, 160, 782
Krolewski, A. S., S40
Foster, A., S27 Hara, H., SI 33 Jabbar, A., 189
Kullberg, C. E., 1027
Foster, A. V. M., S61 Hara, T., 120 Jackson, j. G. L., 9, 389, 411
Foster, J. E., 973 Harada, Y., 330 lain, S. K., 59 Kumar, S., 139, 915
Fox, C., 592, 915 Harding, S. P., 850 jardine Brown, C., S43 Kuzuya, T., S59, SI 09, SI 20, 365
KvasniCka, J., 800
Fraser, H. S., 574 Hardisty, C. A., 634 Jarrett, R. j., SI 5
Freeman, D., S27 Harell, D., 457 Jeffcoate, W. )., 170, 510, 514 Labbrozzi, D., 1017
French, J. M., 741 Harkless, L. B., 192 Jefferson, I. G., 789 Lacigova, S., 156
Frier, B. M., 346, 669 Harris, M. I., S9 Jennings, M. K., 47 Laing, P., 561
Froguel, P., S96 Harris, N., 634 Jensen, T., S33 Laker, M. F., 894
Fujimoto, W. Y., S7, S63 Harris, P. L., 726 Jermendy, G., 916 Lancaster, T., SI 01
Fujita, )., 53 Hatcher, T., S65 Jerums, G., 40 Lankester, J., SI 01
Fukui, I., 53 Hattemer, A., 894 Jervell, J., 847 Larsson, S., 729
Fuller, )., S101 Hebbard, G. S., SI 6 Jiang, C. E., 663 Lassmann-Vague, V., 1051
Fung, A. T. W., 65 Hegazy, M., 337 Jones, K. L., SI 6 Lau, M. S. W., 429
Heine, R. J., SI 2, 482, 960 Jones, S. M., 726 Laurenti, O., 642
Gadsboll, N., 450 Heinemann, L., 625, 683 Jonsson, P. M., 1056 Lavery, L. A., 192
Gadsby, R., S27 Heise, T., 625, 683 Jorgens, V., 536 Law, C. M., S49
Gafni, A., S25 Heller, S., S65 Joseph, S. E., 1072 Law, G. R., 734
Gamsu, H., S43 Heller, S. R., 607, 634 Judd, P. A., 358 Lean, M., SI 01
1076
INDEXES
Drn
INDEXES
Lee, K. K. C., 429 Meeking, D. R., 587 Ostman, )., 1056 Rodgers, FI., 741
Leese, G. P., 401, 850 Melander, A., 520, 5143 0'5ullivan, D. J., 768 Rolfe, M., 996
Leibovici, L., 457 Melchior, T., 450 Overmann, H., 536 ROnnemaa, T., 828
Leiper, |. B., S6 Meneilly, G. 5., 771 Owens, D. R., 519 Rosenqvist, U., 1056
Lemne, C., 1000 Metzger, C., 156 Ross, G. P., 748
Leonetti, D. L., S63 Migdalis, 1. N., 434 Pagano, G., 889 Rosso, D., 771
Leoni, L., 642 Miles, K., 590 Page, R. C. L., 170 Rostami-FHodjegan, A., 634
Lernmark, A., 209 Min, H.-K., 513 Page, 5. R., 764 Rothman, D., 513, 543, 565,
Liberati, A., 1017 Mitchell, T. H., 768 Pajunpaa, H., 382 5101, 5122
Lillioja, S., 5127 Mitcheson, |., 341 Palmer, M., 478, 729 Ruffell, A., 590
Lindgren, M., 218 Mitrakou, A., 533 Pan, C. Y., 663 Ryder, R. E. )., 916
Lindow, S. W., 589 Moghetti, P., 709 Panagiotopoulos, 5., 40
5abatini, D., 321
Lcx)k, D., 594 Mohamed AM, V., 59, 753 Parker, R., 1033
5ackey, A. H., 789
Lorini, R., 630 Mohan, V., 715, 1038 Parthiban, A., 715
5akamoto, N., 120
Lu, ). M., 663 Moio, N., 321 Peacey, 5. R., 634
5alinto, M., 376
Lu, X. P., 663 Molyneaux, L. M., 748 Peacock, L, 543
5amaras, K., 780
Lunt, H., 525, 1009 Montana, E., 683 Pecoraro, R. E., 549
5amartzis, M., 434
Lutterman, |. A., 548 Moosvi, 5., 189 Peja, M., 254
5amuel, A., 284
Luzio, 5. D., 519 Mooy, ). M., 512 Pentecost, B., 5101
5ane, T., 165
Morabito, A., 259 Perez, M., 683
Maassen, |. A., 420 5anjeevi, C. B., 209
Morgan, A. G., 514 Perros, P., 669
MacCuish, A. C., 782 5ano, T., 120
Morgan, L., 514 Peters, ]., 683
Macdonald, 1. A., 511, 112, 607, 5asaki, H., 120
Morgan, L. M., 358 Peters, |. R., 273
634 5astry, N. G., 1038
Morley, M., 495 Phillips, D. I. VV., 325, 771
MacFarlane, I. A., 996 5atoh, 5., 5103
Morocutti, A., 1071 Phillips, W. T., 544
Mackie, A. D. R., 90 5attar, N., 782
Motta, M., 771 Piccoli, A., 642
MacKinnon, M., 590, 5122, 295 5aukkonen, T., 464
Moyses, C., 534 Pickup, |. C., 284
Mackintosh, A-M., 780 5avilahti, E., 464
Muggeo, M., 709 Picou, D. 1., 574
Mackness, M. I., 139 5caramuzza, A., 630
Miihlhauser, L, 536 Pill, R. M., 683
MacLeod, K. M., 346 5chaper, N. C., 523, 555
Muller, H. W., 682 Pimenta, W., 533
Maeda, K., 679 5chraer, C. D., 555
Muller, 5., 646 Plant, M., 56
Mahabir, D., 574 5chvarcz, E., 478
Murakami, M., 902 Polonsky, K. 5., 590
Mahdi, G. 5., 389 5chwartz, J. G., 544
Murashima, 5., 266 Pomposelli )r, F. B., 543
Mansfield, M. W., 720 5corpiglione, N., 1017
Murata, K., 266 Pooke, M., 527
Maravall, |., 683 5culpher, M., 513
Murchison, L. E., 281 Porta, M., 594
Marenah, C. B., 514 5eeman, E., 40
Murphy, M., 577, 5122, 399 Porte |r, D., 525
Mari, E., 1017 5egalini, G., 259
Murphy, N. |., 555 Porter, A., 457
Marrink, J., 651 5eino, Y., 53
Murray, H. )., 979 Pound, N., 510
Marseglia, G. L., 630 5ekihara, H., 5103
Musacchio, N., 259 Powrie, 1. K., 238
Marshall, 5., 56 5elby, P., 284
Premalatha, G., 1038
Martin, B., 513 Nagai, M., 330 5ENDCAP 5tudy Group, 247
Press, V., 5101
Martin, B. C., 540 Nagi, D. K., 59, 753 5eno, M., 53
Price, D. A., 97
Martin, C., 175 Nakagawa, T., 266 5eymour, FI. R., 908
Prigeon, R. L., 563
Martin, 5. C., 594 Nakayama, M., 120 5hanmugasundaram, K. R., 715
Massi Benedetti, M., 1017 Nasrat, H. A., 861 5harp, P., 247
Masson, E. A., 589 Nattrass, M., 30 Quattrin, 5., 321 5haw, )., 592
Mather, H., 247 Nauck, M., 539 Quin, |. D., 908 5haw, J. E., 530, 1033
Mather, H. M., 284 Naylor, A. R., 281 Qureshi, R., 189 5haw, K. M., 238, 520
Mathias, L., 420 Negishi, K., 330 5haw, M., 175
Matsuda, A., 559 Negri, C., 709 Raccah, D., 1051 5hibazaki, 5., 330
Matsumae, H., 120 Nicholls, J. 5. D., 226 Rad ice, M., 259 5higeta, Y., 365
Matsumura, K., 266 Nicholls, M. G., 150 Rahim, F., 189 5hima, T., 266
Matsuo, 5., 120 Nicolaides, A., 247 Ram, P., 125 5hor, R., 97
i Matthews, D. R., 553 Nicolaides, K. H., 90 Ramachandran, A., 232, 420 5hore, A. C., 160
Mattock, M., 1071 Nicolucci, A., 1017 Rauwerda, J. A., 539 5ibilio, G., 321
Mattock, M. B., 284 Nijpels, G., 512 Rebrin, K., 567 5igal, R. )., 540
Maughan, R. J., 56 Nishi, 5., 902 Reckless, |., 513 5ilink, M., 65
McAuliffe, A. V., 758 North, T., 560 Regev, A., 457 5immons, D., 371
McCabe, C., 561 Nounopoulos, C., 434 Rehman, A., 189 5inha, A., 40
McCarthy, M., 420 Nystrdm, L., 495, 1056 Reiber, G. E., 56 5ivieri, R., 594
McCarthy, M. I., 232 Reijonen, H., 464 5j6berg, L., 165
McCollum, P., 726 Obayashi, H., 53 Renton, 5., 247 §krha, J., 800
McEvilly, E., 554 O'Brien, 5. F., 520 Reunanen, A., 376 5loan, P., 530
McGuire, A., 683 Odawara, M., 1072 Richmond, W., 247 5luiter, W. J., 651
Mclnnes, A., 565 Ohir.maa, A., 382 Rigas, K. L., 243 5mith, D. G., 549, 967
McKinney, P. A., 734 Oka, Y., 598 Ripoll«, J.. 953 5mith, U., 531
McLarty, D. G., 990 Olmos, J. M., 284 Rizza, R., 523 5nehalatha, C., 232, 420
McLennan, 5. V., 145, 758 Osmond, C., 868 Roberts, 5., 590 5nowden, R., 560
McLeod, C., 590 Osterode, W., 1044 Robinson, 5., 868 5oeldner, J. 5., 540
McNally, P. G., 594 Ostler, J., 543 Rocca, A., 259 5oler, )., 683, 953
1077
INDEXES
Dm
INDEXES
Soliman, A. T., 582 Thomaseth, K., 709 Vamosi, I., 254 Westermark, P., S46
Sorensen, K. E., 834 Thompson, T. |., 337 Van Acker, K., S61 White, A., S90
Sous, E. S., 337 Thordarson, H., 495 van der Feltz van der Sloot, D., White, M., 561
Sovik, O., 495 Tian, H., 663 482 Wijkel, D., 482
Spencer, M.-|., S30 Tillmann, V., 97 van der Meer, J. W. M., S48 Wilcox, M., 170
Staines, A., 734 Tobe, K, SI 03 van Doom, L. G., 794 Wilke, R. A., 771
Starke, A. A. R., 625, 683 Toft-Nielsen, M., 544 van Houtum, W. H., 192 Wilkinson, SI 3
Steel, )., S43 Tognoni, G., 1017 VanderMeulen, |., 23 Williams, D. R. R., 273, 389,
Steen, L., 471 Tomlinson, B., 150 Vanderpump, M. P. 741 734
Stehouwer, C. D. A., 102 Tomlinson, D. R., 679 Vardhan, A., 771 Williams, R., SI 22
Steil, G., S67 Tooke, ]., S77 Vaughan, N., SI 3, SI 22 Wills, J., 771
Stein, C., 325 Tooke, ). E., S26, 160, 973 Vaughan, N. |. A., 175, 182 Wishart, |. M., SI 6
Stenberg, C., 218 Torffvit, O., 487 Veglio, M., 594, 771 Wolfe, J., S27
Stensel, V. L., 549 Torp-Pedersen, C., 450 Vennart, W., 973 Woo, |., 150
Sterky, G., 1056 Tosi, F., 709 Vertommen, |., 415 Woodward, C., S60
Stewart, M. W., 341, 894 Tovey, F., S27 Vervoort, G., 794
Stockman, A. |., 160 Toy, J., S77 Vialettes, B., 1051
Yagi, T., 902
Stott, N. C. H., 683 Tran, T., 420 Viberti, G. C., 1071
Yamakido, M., SI 33
Stratton, I. M., 656 Trautmann, M. E., 625 Viberti, G.-C., S6
Yamashita, K., 1072
Sturrock, N. D. C., 510 Tremble, |., 1069 Vignati, L., 47
Yamauchi, T., SI 03
Sumida, Y., 266 Trento, M., 594 Viikari, ). S. A., 828
Yao, C., 663
Swaminathan, R., 150 Tritos, N. A., 243 Vijayalingam, S., 715
Yazaki, Y., SI 03
Swift, P., S54 Tsalamandris, C., 40 Visser, P., 651
Yehezkelli, Y., 457
Swinburn, B. A., 695 Tsapogas, P. C., 243 Viswanathan, M., 232, 420
Yki-Jarvinen, H., S33
Tsuda, K., 53 Vora, |. P., 401, 850
Yokoyama, H., 313
Tucker, G. T., 634
Yoshimi, T., 902
Tada, K., 1072 Tunbridge, F., 741
Yoshinaga, H., SI 09, SI 20
Takahashi, K., 330 Tunbridge, W. M. G., 741 Wagener, W., 536
Young, A., S34
Takeda, H., 266 Tuomilehto-Wolf, E., 464 Wahl, L. Ch., 625
Young, E. T., 741
Takolander, R., S39 Turnbull, D. M., 133, 341 Waiji, S., 59
Young, M. |., 979
Talbot, F., SI 3 Turner, R. C., 656 Walker, M., 133, 341, 392
Young, R. I., SI 22
Tamemoto, H., SI03 Turtle, I. R., 145, 748, 758 Wall, S., 1056
Young, R. P., 429
Tan, K. C. B., 816 Tuvemo, T., 97 Walls, ]., S6
Yudkin, J. S., SI 6, 59, SI 01, 389,
Tanudjaja, T., 156 Walmsiey, D., 281
Ueki, K., SI 03 753
Tattersall, R. B., 112 Walsh, C. H., S58
UK Prospective Diabetes Study Yue, D. K., 145, 748, 758
Taub, N. A., 238 Walton, C., 589
Group, 656
Taylor, K. P., 868 Ulberth, F., 1044 Wang, S. Y., 663 «
Taylor, K. W., 910 Wang, Z. S., 663 Zachariadis, D., 434
Ulbrecht, |. S., SI 7
Taylor, R., 325, 946 Warram, J. H., S40 Zhang, X. L., 663
Unwin, N., S27, 72, 874, 990
Taylor, R. W., 133 Watanabe, R., S67 Ziegler, D., S34
Teramo, K., 165 Vaag, A., 806 Watkins, P. |., 1007 Ziegler, O., 646
Terauchi, Y., SI03 Vague, P., 1051 Watson, |. M., 771 Zilkens, R. R., 145
't Hart, L. M., 420 Vahatalo, M. A., 828 Watts, G. F., 238, 520 Zimmet, P., 501
Thirlwall, M., S65 Valensi, P. E., 882 Welch, A., 226 Zimmet, P. Z., 125, 441
1078
INDEXES
pm INDEXES 1
KEY WORD INDEX
a-adrenoreceptors, 983 Bile-acid sequenstrating agents. Development of NIDDM, SI09, 273, 337, 371, 536, 555, 734,
A4166, SI 51 297 SI 20 967
Aat II genotype, 720 Biomechanics, SI 7 Diabetes, S6, 40, 80, 84, 165, Erectile dysfunction, 84
Acarbose, SI 43 Biothesiometer, 561 281, 371, 376, 382, 411, 561, Erectile failure, 700
ACE inhibitor, 120 Birth weight, S37 700, 726, 764, 816, 1009 Erythrocyte aggregation, 646
Activity, 273 Birthweight, 226 Diabetes care, 175, 182 Eskimos, 555
Acute insulin response, S25, S40 Blindness, 850 Diabetes Mellitus, 850 Essential hypertension, 504
Acute insulin response to IVCTT, Blood glucose, 80, 510, 789, 927 Diabetes mellitus, SI 6, S23, S23, Estimated food record, 656
SI 09 Blocxi glucose, S6 S33, S34, S43, S52, 72, 156, Ethnicity, 226, 748
Adolescence, 97 Blood viscosity, 1044 192, 254, 273, 297, 358, 415, Euglycaemic clamp, SI 27
Adolescents, 65, 254, 531 Body composition, 40 487, 493, 520, 574, 589, 616, Exercise, 908
Aetiology, 734 Body mass index, 72, 549 642, 663, 669, 741, 768, 789, Exercise test, 259
Age, 510 (British) Diabetic Association, 9 898, 908, 979, 990, 996, Extracellular matrix, S30, 313
AIR„„., S25 1033, 1056
Alaska Natives, 555 Calcinosis, 768 Diabetes prevention, S9, S20 Factor analysis, 564
Albuminuria, 150 Callus, 979 Diabetic, 587 Familial aggregation, 232
Aldose reductase inhibitors, 1017 Capillary density, 160 Diabetic complications, 828 Familial non-insulin-dependent
Ambulatory blood pressure, 531 Capillary filtration, 882 Diabetic diet, 656 diabetes mellitus, 133
Ambulatory care, 1056 Cardiac function, 259 Diabetic foot, SI 7, S26, S39, Family history of NIDDM, 434
American Indians, 555 Cardiovascular autonomic S48, S52, S55, S58, S61, 156, Fast absorbable carbohydrates.
Amputation, 192, 371, 726 control, 709 549, 912 625
Amputations, S6 Cardiovascular disease, SI 5, 125, Diabetic foot ulcer, 967 Fasting, 894
Amylin, S34, S46 927 Diabetic foot ulcers, 1064 Fasting hyperglycaemia, 861
Amyloid, S46 Cardiovascular risk factors, 72, Diabetic gastroparesis, 112 Fasting IRI, SI 09
Angiotensin converting enzyme 441 Diabetic microangiopathy, 882 Fatty acid binding protein-2, 902
inhibition, 401 Case-control studies, 1056 Diabetic nephropathy, 145, 401, Feet, S6
Ankle pressure index, 549 Caucasians, 960 758, 1033 Fetal, S49
Ankle tendon reflexes, 960 CETP, 139 Diabetic neuropathy, 679, 768, Fetal growth, 325, 868
Ankle-arm index, 967 Charcot joint, S52 973, 1027, 1033, 1064 Fetal macrosomia, 170
Anti-muscarinic agents, 493 Childhood, 734 Diabetic peripheral neuropathy. Fetal outcome, 90
Anti-thyroid peroxidase Children, 254 S34, 1017 Fibric acid derivatives, 297
antibodies, 415 Chinese, 150 Diabetic retinopathy, 946 Fibrocalculous pancreatic
Antidiabetic agents, SI43 Chiropody, S58 Diabetic ulcers, S30 diabetes, 1038
Antimicrobial therapy, S48 Cholecystokinin-8, S44 Diagnosis, S34, 337 Fibrosis, S46
Antioxidant enzymes and Cholesterol, 297 Diagnostic criteria, S6 Fiji, 125
scavengers, 715 Cholesteryl ester, 139 Diastole, 834 First degree relatives, 953
Aortic valve stenosis, 768 Cholesteryl ester transfer, 139 Diastolic function, 321 Flavonoids, 882
Apolipoprotein C-ll, 902 Chronic renal failure. 514 Dietary fibre, 358 Follow-up study, S40
Apolipoproteins (apo Al, apo B), Chronic wounds, S30 Dipeptidyl-peptidase IV (DPP-IV), Foot, 192
150 Clinical examination, S55 SI 56 Foot care, S61
Arterial ultrasonic score, 247 Coeliac disease, 464 Diposition index, S67 Foot complications, 561
Asian Indians, 232 Cognitive Function, 218 Discordant twins, 806 Foot deformities, S52
Aspiration, S6 Cognitive function, 607, 634 Disease prediction, 399 Foot pressure, SI 7
Atherosclerosis, S23, S26, S43 Combination therapy, SI 43 District Register, 175 Foot pressures, SI 2, 912
Atherosclerotic vascular disease. Complications, 156, 189 District register, 182 Foot ulceration, SI 2, 973, 979
313 Computers, 182 Diurnal variation, 531 Footwear, SI 7, S58, 1064
Audit, 182 Congestive heart failure, 450 Dyslipidaemia, 150 Free insulin, 1051
Audit computers, 175 Contraception, 1009 Dyslipoproteinaemia, 297 Free tissue transfer, 281
Autonomic dysfunction, 1038 Contrast medium, 487 Fructosamine, 514, 789
Autonomic function, 254 Controls, 478 Early hyperglycaemia, 715 Fundus photography, 482
Autonomic neuropathy, 65, 549, Cord plasma insulin, 868 Eating disorders, 1009
983, 1033 Coronary heart disease, SI 6, 297, Echo-Doppler cardiography, 834 Gangrene, 156
Autonomic Neuropathy, 259 782 Economics, 273 Gastric emptying, S6, S11, SI 6,
Axonal transp)ort, 679 Costs, 273 Ecstasy, 908 S28, S31, S34, S39, S44, 112
Counterregulation, 346, 544, 634 Education, S58, S61, 536, 908 Gastric secretion, S6
/3-cell, S63 Cow's milk, 23 Egypt, 337 Gastrointestinal symptoms, 478
^-Cell failure, SI 27 C-peptide, S25, S63, 330 Ejaculatory failure, 700 Gastroparesis, SI 6
^-cell loss, S98 Critical limb ischaemia, 726 Enalapril, 120 Genetic susceptibility, 209
BDA, 898 Enterogastrone, SI 56 Genetics, S67
Behavioural change, 564 Denervation hypersensitivity, 983 Enterovirus, 910 Genetics of diabetes , S90
Beta-blockade, 544 des 31,32 proinsulin, 753 Environmental factors, SI 33 Gestational diabetes, 226, 748,
Biguanides, SI 43 Developing countries, 574 Epidemiology, S6, S9, S34, 192, 861
© 1996 by John Wiley & Sons, Ltd. DIABETIC MEDICINE, 1996;13:1079-1081 1079
Gestational diabetes mellitus, 189 Hypoglycaemia, S28, 346, 589, Insulin-dependent diabetic MELAS, 420
Cliadin antibodies, 464 634 patients, 625 Membrane LPO, 715
Glomerular function, 487 Hypoglycaemia ,218 Insulin-treated diabetes, 564 Menstrual cycle, 525, 1009
Glucagon, S34, S39, 544 Hypoglycaemia awareness, 634 Intensified insulin therapy, 536 Meta-analysis, 1017
Glucagon-like peptide, S39 Hypoglycaemia unawareness, Intensive insulin therapy, 794 Metabolic control, 478
Glucagon-like peptide-1, SI 56, 346, 607 Intermediary metabolism, 30 Metabolic programming, 868
854 International studies, S9 Metabolic syndrome, 874
Glucagon-like peptide-1 receptor, IDDM, S28, 313, 651, 734, 794, Intervention trials, 938 Metabolism, 616
902 910 Intima media thickness, 247 Metformin, 753
IDDM in children, 582
Glucokinase, S37 Intra-abdominal fat, S63 Micro-haemorrhage, 973
IGT, 330
Glucokinase gene, S96 Intracavernosal injections, 84 Microalbuminuria, 120, 145,
Ileal brake, SI 56
Glucose, S63 Intracellular free calcium-ion 401, 441, 520, 764, 889
'^’l-MIBG Myocardial
Glucose absorption. S11 concentration, 53 Microangiopathy, S26
Scintigraphy, 266
Glucose clamp, 709 Intracellular sodium Microcirculation, 160
Immune response, 630
Glucose effectiveness, S67, S78 concentration, 53 Migration, S7
Immune-mediated diseases, 630
Glucose fatty acid cycle, 806 Intraperitoneal insulin, 1051 Mitochondria, 420
Impaired development, 160
Glucose homeostasis, S23 Intravenous glucose tolerance Mitochondrial gene mutation,
Impaired glucose tolerance, S6,
Glucose metabolism, S148 test, SI 27 S98
S9, SI 2, SI 5, S23, S25, S40,
Glucose tolerance, 953, 960 IRS-1, SI 03 Mobile unit, 946
S63, SI 27, 160, 663, 715,
100 g Glucose tolerance test, IRS-2, SI 03 Morbidity, 376
854, 927, 938
861 Ischaemia, 281 Morphometry, 675
Impaired Glucose Tolerance, S20
Glucose transport, S87 Islet amyloid polypeptide, S46 Mortality, 125, 192, 729, 927,
Impotence, 700
Glutamate decarboxylase 65, 209 Islet cell antibodies, 415 967, 990
Incidence and prevalence, 582
Glutathione peroxidase, 1044 Islet function, S25 Muscle glucose uptake, S33
Incidence of non-insulin
Glycaemic control, SI 6, S34, Italy, 889 Muscle glycogen synthase, 806
dependent diabetes mellitus
S34, 457, 510, 536, 564, 889, Myocardial autonomic
(NIDDM), SI 33
1027 japan. S11 neuropathy, 266
Infant influences, S49
Glycated albumin, 646 japanese-Americans, SI 33 Myocardial Infarction, 80
Infant nutrition, 23
Glycated haemoglobin, 514 Myocardial infarction, 450
Infection, S48, 156, 457, 912
GGGGGlllruyyyoacccwrooo tggpshyeuy, lnmra9r to,7se lyd a3n t5eth8h,a ae4sm9e3,o g3l2o5b in, 243 IIInnnfss7euu0rlltii9innl,i, t ya7Sc,5 3t37i9o 0,n 05, 9S, 6574, 4S, I64384 , 642, KKKKaielneltloibinkassicr,ee ildi6lnao4 s2isins p,h. ,i 5b48it57o7,r s9, 0684 2 NNNaee5uop3rnh6uar,,ot ap47la4 6tc14ha yre, ,9 900, 165, 313, 371,
Guidelines, 574 Insulin action enhancer, 365 Nerve biopsy, 675
Gustatory sweating, 493, 1033 Insulin adjustment, 525 Labelled albumin, 882 Nerve growth factors, 679
Insulin analogue, 47 Late diabetic complications, 238 Nerve injury, 677
Insulin analogues, 625 LCAT, 139 Neuroarthropathy, S52
HbA,, 510 Insulin autoantibodies, 415 Left ventricular function, 450, Neuropathy, S26, S31, 979
HbA,„ 1027 Insulin beta cell function, S25 834 Neurotrophic factors, 677
Health care, 376 Insulin deficiency, SI 61 Left ventricular mass, 321 NIDDM, SI 6, SI9, S25, S40,
Health services/utilization, 1056 Insulin discovery, 9 Leucocytes, 145 S49, S78, S85, 139, 150, 420,
Healthy subjects, SI 9, 478 Insulin kinetics, 1051 Limited joint mobility, SI 2, 828 715, 758, 782, 953
Heart rate spectral analysis, 709 Insulin lispro, 47 Lipid peroxidation, 715 NIDDM , S148
Heart rate variability, 266 Insulin receptor substrate, S87 Lipolysis, 30 NIDDM aetiology, SI 27
Height, 97 Insulin receptor substrate-1, 133, Lipoproteins, 139 NN623, S151
Hepatic gluconeogenesis, S23 341 Logistic model, 536 Nocturnal hypoglycaemia, 794
Hepatic glucose output, S33 Insulin receptors, S87 Longitudinal, 65 Nocturnal penile tumescence, 84
Hepatic glucose production, Insulin resistance, SI 6, 30, S33, Low insulin response to OGTT, Non-insulin dependent diabetes
SI 56, 544 S63, S78, S85, S90, SI 03, SI 09, SI 20 mellitus, SI 3
Hepatitis B vaccination, 630 SI 27, 133, 150, SI 61, 325, Low insulinogenic index, SI 09 Non-insulin-dependent diabetes,
Hexokinase II, 902 341, 365, 429, 441, 504, 806, Lower extremity arterial disease, S31, S44, 120, 720, 806
High pressure, 979 874, 953 243 Non-insulin-dependent diabetes
High-density lipoprotein, 297 Insulin resistance syndrome, 720 mellitus, S11, 125, 243, 321,
History, 9, 411 Insulin response, S23, S59 Macrosomia, 861 337, 341, 450, 471, 504, 555,
HLA-DQ, 209 Insulin secretion, SI 9, S25, S33, Magnetic resonance imaging, 973 854, 927, 938, 1038
HLA-DR, 209 S37, S67, S78, S90, 816, 953 Malondialdehyde, 800 Non-invasive vascular
Hormonal regulation, S11 Insulin secretory capacity, SI 3 Mapping, 734 assessment, S39
Hormone replacement therapy, Insulin secretory defect, S98 Maternal excess, 420 Non-obese, SI 3
782 Insulin secretory rate, S25 Maternal history, 232 Non-sulphonylureas, SI 51
Hospitalization, 376 Insulin sensitivity, SI 3, SI 9, S25, Maternal nutrition, 868 Noradrenaline, 983
Human insulin, 346 S40, 589 Matrix degradation, 145 Normotension, 120
Humulin ®R, 47 Insulin therapy, 9, 40 Maturity onset diabetes of the Nottingham Health Profile (NHP),
Hyperglycaemia, S31, 358 Insulin tolerance test, 429 young (MODY), S96 382
Hyperglycemia, S23 Insulin treatment, 471, 1051 Maturity-onset diabetes of the Nutrient intake, 656
Hyperinsulinaemia, 434, 874 Insulin-dependent diabetes, 170, young (MODY), S90
Hyperlipidemia, S23 238, 346, 510, 531 Maximum entropy method, 266 Obesity, 40, S63, S85, 616, 874
Hyperlipoproteinaemia, 297 Insulin-dependent diabetes Meal composition, S11, S31, S44 Offspring, 434
Hypertension, 401 mellitus, 209, 399, 464, 504, Medical ethics, 399 OGTT, S59
Hypertriglyceridaemia, 816 630, 834, 983 Medical staffing, 669 75-g OGTT, 330
1080
INDEXES
Dm
INDEXES
Oman, 582 Pregnancy, 90, 165, 170, 589 Serum insulin, 247 Treatment failure, 471
Oral glucose tolerance test, S6, Prevalence, S7, S11, 189, 663 Sexual desire, 84 Triglyceride, 59
SI 27 Prevention, S55, S58 Shoes, 1064 Triglycerides, 297, 434, 894
Oral hypoglycaemic agent, 365 Primary health care, 482 Sialic acid, 238 Tubular function, 487
Oscillatory insulin secretion, S53 Private practice, 574 Skinfold thickness, 97 Twenty-year incidence data, 741
Outcome, 457 Proglucagon, SI 56 Slowly progressive IDDM, S98 Type 1 (insulin-dependent)
Outpatient appointments, 669 Programming, 325 Smoking, 72, 536, 549, 996 diabetes mellitus, 729, 1027
Outpatient clinics, 669 proinsulin, 753 Social consequences, 729 Type 1 diabetes, 23, 97, 478,
Proinsulin, SI 9, S25, 59, 330 Socio-economic status, 72, 898 525, 607, 646
Palpation of pedal pulses, 561 Prospective study, SI 20, 967 Sodium-lithium countertransport Type 1 diabetes mellitus, 47, 65,
Pancreatic polypeptide, 528 Puberty, 97 activity, 53 90, 828, 1044, 1051
Papua New Guinea, 441 Public facilities, 574 South Asians, SI 6 Type 2 (non-insulin dependent)
Pathogenesis, SI 2, S34, 910 South India, 420 diabetes, 325
Pedal bypass graft, 281 Quality of health care, 574 Specific insulin, 960 Type 2 diabetes, S39, 53, 232,
Peripheral ischaemia, S39 Quality of Life, 382 32-33 split proinsulin, 868 247, 365, 434, 482
Peripheral neuropathy, SI 2, 65, Quantitative sensory testing, 960 Staging, S34 Type 2 diabetes mellitus, 160,
677, 912 Questionnaire, 478, 564 Staphylococcus aureus, 457 330, 894
Peripheral vascular disease, SI 2, Statins, 297
192, 912 Randomized clinical trials, 1017 Statistics, 536
Peripheral vascular resistance, Reconstruction, 726 Sub-Saharan Africa, 990 UK dataset, 182
983 Regular human insulin, 47 Sulphonylurea, SI 56, 634 Ulcer, 281
Pernicious anaemia, 411 Renal impairment, 90 Sulphonylureas, S20, SI 43 Ulcers, S6
Phenotypic marker, S53 Reproducibility, 561 Superoxide dismutase, 800 Urbanization, S7
Physical activity, 555, 789 Reticulin antibodies, 464 Sural nerve, 675 Urinary cotinine, 996
Pima Indians, SI 27 Retinopathy, 165, 337, 371, 482, Survey, 726, 889 Urinary glucose, 651
Plasma proteins, 646 536, 850 Susceptibility to non-insulin- Urinary glycosaminoglycans, 758
Plasminogen activator inhibitor Review, 23 dependent diabetes, 748 Urinary IgG, 651
(PAI-1), 59 Risk factors, S6, S7, 243, 741, Symptomatic treatment, S34 Urinary infection, 520
Pneumomediastinum, 587 927, 938 Symptoms, SI 6, 346
Podiatry, S55 Risk of diabetes, 232 Systematic reviews, 1017 Vagal nerve, S28
Polynesians, 371 Vascular disease, S23
Population-based survey, 960 Scintigraphy, S6 The Doctor's Dilemma, 411 Vascular surgery, S43
Postprandial levels, 894 Screening, 482, 561, 741, 946 The Netherlands, 192 Venous sampling, 429
Postprandial lipoprotein Screening programmes, 764 Thiazolidinedione, 365 Vibration perception, 1027
metabolism, 816 Secondary sulphonylurea failure, Thiazolidinediones, SI43, SI48 Viscosity, 358
POT II, S44 S98 Tissue plasminogen activator, Vitamin A, 1044
Power Spectral Analysis, 266 Selenium, 1044 PAI-1, 800 Vitamin E, 1044
Pramlintide, S34 Self-management, 564 Tolbutamide, 634 Von Willebrand factor, 720
Prandial glycaemia, 625 Self-monitoring, 894 Transcutaneous oxygen, 549
Pre-diabetes, S37 Self-monitoring of blood glucose, Transforming growth factor-/3,
Predictor, 330 794 313 Waist-to-hip ratio, 243
Predictor of lapanese NIDDM, Semmes-Weinstein Transmitral flow, 834 Waiting time, 669
SI 09 monofilaments, 561 Treatment, 854 Work capacity, 254
I
1081
INDEXES